In this study, which enrolled 64 patients with pretreated EGFR-mutant NSCLC, the ORR was 34%, with a median duration of response of 9.6 months and a mPFS of 9.3 months. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.